Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy Meeting Abstract
| Authors: | Scher, H. I.; Logothetis, C.; Molina, A.; Goodman, O. B.; Sternberg, C. N.; Chi, K. N.; Kheoh, T. S.; Haqq, C. M.; Fizazi, K.; De Bono, J. S. |
| Abstract Title: | Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy |
| Meeting Title: | 2011 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2011 Feb 17-19 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-03-01 |
| Language: | English |
| ACCESSION: | WOS:000208880700005 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2011.29.7_suppl.4 |
| Notes: | Meeting Abstract: 4 -- Source: Wos |
